Victoria Socha
Articles by Victoria Socha
Does the prevalence of cardiovascular-kidney-metabolic syndrome stages vary by social determinants of health?
Is time to death from withdrawal of life-sustaining treatment is associated with kidney transplant outcomes?
The TRANSNEMIA study addressed the need for guidelines specific to anemia in kidney transplant recipients.
Researchers studied variation in AKI incidence with IV antihypertensive treatment after severe hypertension.
A study examined the efficacy and safety of conversion from treatment with the long-acting ESA MPG-EPO to vadadustat.
A global review noted changes in kidney care delivery but revealed gaps in access to kidney replacement therapies.
A study examined the impact of hemodiafiltration versus hemodialysis in patients with end-stage renal disease.
CERTAIN registry data were used to assess age-related differences in outcomes among pediatric kidney transplant recipients.
Researchers studied the clinical relevance of allograft microvascular inflammation in kidney transplantation.
Development of a transplant morbidity gene panel highlights how genetic testing could open the door to personalized care.
Researchers studied outcomes of transplant recipients who received kidneys from toxoplasma-positive versus negative donors.
A study examined an association between hyperglycemic crises at diabetes diagnosis and a higher risk of developing CKD.
Researchers evaluated efficacy and safety of allopurinol versus febuxostat for gout in patients with stage 3 CKD.
BTK inhibitor zanubrutinib was found to be well tolerated and showed activity in patients with membranous nephropathy.
Semaglutide reduced the risk of death among patients in the FLOW trial, who had CKD and type 2 diabetes.
Finerenone did not modify kidney outcomes but reduced albuminuria and risk of new-onset macroalbuminuria in patients with HF.
A trial assessed an acellular tissue engineered vessel (ATEV) compared to autologous arteriovenous fistula for hemodialysis.
Pegcetacoplan achieved significant reductions in proteinuria and C3c staining and stabilized eGFR in patients with C3G.
FLOW trial data showed semaglutide safely reduced risks of major kidney outcomes regardless of CKD severity.
A novel endothelin receptor type A selective antagonist showed a meaningful reduction in proteinuria in patients with IgAN.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.